Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Advances in Vial Processing in Pharmaceutical Primary Packaging to Reduce Risk of Vial Damage and Particle Contamination

By John Erdner, Aseptic Fill-Finish Systems, SP Scientific PennTech | March 26, 2019

There has been at least one recall for parenteral products packaged in vials with chipped rim surfaces and a number of US Food & Drug Administration (FDA) 483 notices issued to pharmaceutical manufacturers for glass particles found in vials. When this occurs, it is obviously a critical event for the manufacturer of parenteral products.

Sometimes these instances can go undetected—the vial progresses to filling, is stoppered and capped before inspection. If the vial is capped, this defect will be difficult to identify.

Manual inspection and most automated inspection systems use rear-source lighting to look for particles within the product. Particles block the light and appear as black spots, however, glass particles are easily missed in this process. Some more advanced inspection systems are entering the market which use bottom-source lighting to help identify fibre and glass fragments via reflectance measurement, however, these are costly and it would be prudent and more efficient to address the issue of glassware damage at its source.

Figure 1: Chipped vial rim and resultant particulate generation.

Sources of Glassware for the Filling Line

Glass vials may be sourced and then washed and sterilized prior to filling as part of a continuous process, which is typical for higher throughput lines filling larger batches. Here, glass vials are washed to remove loose particles from the inside and outside of the vials; vials are then feed through a depyrogenation tunnel for sterilization. Vials leaving the tunnel enter the most sterile area of the facility and are now ready to be filled.

Many smaller batch applications use pre-sterilized glass supplied directly to the filling station as a cost- and space-saving alternative to operating a washing and sterilizing line. Pre-sterilized glass vials are washed and depyrogenated by the supplier, double bagged and then gamma irradiated to sterilize before being shipped to the end user for use.

This convenience, however, may introduce additional risk to the process. Even though the glass is sealed to protect against contamination, the glass is not under full control during shipment where vibration and manual handling are inconsistent. Typically, the vials are tightly bagged to hold them together in a formation or pack. Vials rub against each other or may collide if the pack loses shape, leading to damage, seen as cracks and chips, resulting in the creation of glass particles. The use of dividers or other packaging separating the vials for protection is not normally possible as they may compromise sterility or themselves create dust particles.

For small batch applications there are companies that provide a vial washer and tunnel suited to lower throughput processes of 50 vials per minute, or less. Modern systems (Figure 2) are compact, occupying 3m/9ft or less, and are sized for small batches giving the drug manufacturer complete control of the process, thus minimizing the risks of human intervention and contamination.

Figure 2: Modern washing and depyrogenation installation featuring washing needles.

Eliminating Vial Damage During Washing

Vials are usually manually unwrapped and loaded into vial washing machines, when the operators have the opportunity to identify damage or debris and remove the defective glass. Besides transport damage, another cause for chipped vials can be vial washers themselves. Many washing systems use stainless steel needles to transfer the washing media to the inside the vials. The needle enters the mouth of the vial before the washing phase begins.

To achieve high vial throughputs, rotary washers have dozens of needles and some linear washers have hundreds of needles entering the vial multiple times during the washing process. A 2cc vial can have a neck opening as small as 7mm diameter and the spray nozzles may be as thick as 4mm, leaving little clearance.

Thin needles can easily be accidentally bent during storage or installation, or misaligned during set up or service. The result is that the needle impacts the rim of the vial causing chipping to the vial mouth and glass debris.

This interaction between the needle and vial occurs inside the machine during the washing process and is virtually undetectable as the vial is filled, stoppered and capped, and depending on the closure used, may not even be detected during the final inspection process.

The most advanced vial washers have eliminated the use of needles entirely, yet still achieve a 3-log reduction of particles required by the FDA during vial washing. This is accomplished by positioning a vial above the washing manifold which has precisely machined orifices to generate a high velocity water jet.

This design creates a water stream that maintains its convergent nature until it impacts the base of the vial (Figure 3), ultimately eliminating the risk of misalignment and therefore the chipping and debris associated with the use of washing needles.

Figure 3: High pressure washing jet manifold for vial washing without needles.

The use of pre-sterilized glass has inherent risks of glass particles and sterility assurance as the process is outside the drug manufacturer’s control. When introducing a new washing process in-house, vial washers which do not use penetrating needles should be selected to minimize the risk of chipping glass and creating debris. Small systems are available today that fit within smaller facilities, reducing the dependence on supplies of pre-sterilized glassware.

John Erdner is Product Manager, Aseptic Fill-Finish Systems, with SP Scientific PennTech of Warminster, Pa.

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE